The $90 price target has captured investor attention because it represents the highest forecast among all Wall Street analysts covering The Vita Coco Company, Inc. (COCO). Goldman Sachs reiterated its Buy rating and raised its target to $90 following the company's second-quarter 2026 earnings release in late July, while Piper Sandler lifted its own target to $89. The round number also carries psychological significance — reaching $90 would mark a new all-time high, surpassing the stock's 52-week peak of $85.83 and confirming that the long-term growth narrative remains intact.
The Vita Coco Company, founded in 2004 and publicly traded since October 2021, is the dominant force in the global coconut water category. The company commands roughly 50% of the US market and approximately 80% of the UK market. Beyond its flagship coconut water, the product portfolio includes Vita Coco Treats, a plant-based dairy alternative, PWR LIFT, a protein-infused fitness drink, Vita Coco Coconut MLK, and private label offerings for major retailers. The company operates across more than 35 countries through an asset-light model that relies on third-party manufacturing partners in seven countries, giving it flexibility to navigate tariff and supply-chain disruptions. As a certified B Corporation and Public Benefit Corporation, Vita Coco balances profit objectives with social and environmental commitments.
As of the market close on July 27, 2026, COCO shares traded near $67.35, reflecting a market capitalization of approximately $3.8 billion. The stock has delivered an impressive return of roughly 75% over the trailing twelve months but has pulled back approximately 20% from recent highs above $82 reached in late June. The decline occurred despite strong fundamental performance, as the company reported first-quarter 2026 net sales of $180 million — up 37.3% year over year — and earnings per share (EPS) of $0.50 that beat analyst estimates by nearly 58%. Management also raised full-year 2026 guidance to net sales of $720 million to $735 million and adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) of $132 million to $138 million. The balance sheet remains pristine, with $202 million in cash and zero debt.
International expansion represents the single most compelling catalyst for COCO shares. The International segment, while still only about 17% of total net sales, delivered 72% revenue growth in the first quarter of 2026. The UK and Germany remain central to that opportunity, and the company continues to identify new markets with favorable demographics for coconut water adoption. Domestically, coconut water is steadily transitioning from a niche health product into a mainstream hydration choice, expanding beyond natural food channels into club, convenience, and foodservice distribution. Gross margins also showed improvement, expanding 320 basis points year over year to 39.9% in the first quarter. If Vita Coco can sustain mid-teens revenue growth while gradually expanding margins, the earnings power needed to support a $90 stock price becomes increasingly achievable.
Valuation is the most frequently cited concern. At roughly 37 times trailing earnings, COCO trades at a significant premium to the broader non-alcoholic beverage industry, where peers often trade between 17 and 20 times forward earnings. Management has cautioned that first-quarter growth benefited from the timing of a major club promotion and should not be annualized across the full year. Shipping costs, packaging expenses, energy prices, and tariffs on imported coconut materials all pose ongoing margin risks. Additionally, the company's heavy concentration in a single product category — coconut water accounted for 96% of 2025 sales — leaves limited diversification if consumer preferences shift or competitive pressure intensifies from larger beverage conglomerates like KO (The Coca-Cola Company) or PEP (PepsiCo, Inc.).
According to 11 analysts surveyed by S&P Global, COCO carries a consensus "Buy" rating and an average 12-month price target of approximately $83.89, implying roughly 25% upside from current levels. The target range is notably wide: the lowest stands at $68 while Goldman Sachs leads at $90. Following the most recent earnings report, Piper Sandler raised its target from $74 to $89, Bank of America maintained its $85 target, Wells Fargo stayed at $85, and Evercore ISI lifted its target to $80. Three firms — Needham, Morgan Stanley, and William Blair — maintain Hold-equivalent ratings, largely citing valuation concerns despite acknowledging operational momentum. The absence of any Sell ratings reflects broad confidence in the business, even if some analysts believe much of the good news is already priced in.
From a technical perspective, the $85.83 level — the stock's all-time high — represents the most significant resistance zone. A successful break above that level on elevated volume would signal broad institutional conviction and could open a path toward $90. On the downside, the $60 to $65 range has provided support during recent pullbacks. The stock's beta of 0.76 suggests lower volatility than the broader market, which may appeal to investors seeking growth without extreme price swings. However, the 20% decline from the June highs demonstrates that even lower-beta names can experience sharp corrections when sentiment shifts.
Navigating a volatile growth story like Vita Coco requires timely and data-driven decision-making. Tickeron's AI Daily Buy/Sell Signals leverage artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on evolving market conditions, technical patterns, and AI-powered analysis. For active traders following COCO, these signals can help identify potential entry and exit points, confirm trend changes, and flag emerging opportunities before they become widely recognized. Whether you are monitoring an existing position or scanning for new ideas, AI-driven signals offer an efficient way to stay ahead of shifting market dynamics.
The question of whether Vita Coco can reach $90 is not a matter of possibility — it is a question of timing and execution. The company possesses genuine competitive advantages: dominant market share in its core category, accelerating international growth, an asset-light and debt-free balance sheet, and a product that aligns with long-term consumer health trends. The strongest analyst on Wall Street has already placed a $90 target on the stock, and earnings momentum continues to trend favorably. However, the premium valuation leaves limited room for disappointment. Any deceleration in international growth, unexpected cost pressures, or loss of market share to larger competitors could quickly erode the multiple investors are currently willing to pay. For COCO to reach $90, the company likely needs to deliver at least one more quarter of better-than-expected results, demonstrate that margin expansion is sustainable, and convince the market that double-digit revenue growth can persist beyond 2026. Investors should monitor international segment performance, gross margin trends, and any changes in analyst estimates as the most reliable indicators of whether that path remains open.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor tells us that COCO and FIZZ have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that COCO and FIZZ's prices will move in lockstep.
| Ticker / NAME | Correlation To COCO | 1D Price Change % | ||
|---|---|---|---|---|
| COCO | 100% | -1.87% | ||
| FIZZ - COCO | 26% Poorly correlated | +1.23% | ||
| MNST - COCO | 23% Poorly correlated | +1.52% | ||
| CCEP - COCO | 22% Poorly correlated | +0.37% | ||
| COKE - COCO | 21% Poorly correlated | +0.74% | ||
| KOF - COCO | 20% Poorly correlated | -0.94% | ||
More | ||||